Georgi Dinkov on T3: The Bioenergetic Case for Pro-Metabolic Thyroid Research
Georgi Dinkov is one of the most prolific voices in the bioenergetic / Ray-Peat-adjacent corner of metabolic research. Across years of blog posts, podcast appearances, and study commentary on his site Haidut.me, Dinkov has built one of the most accessible cases for T3 (triiodothyronine) as a central anti-stress, pro-respiration hormone rather than a narrow thyroid-replacement molecule. His writing has popularized a set of T3 research protocols that diverge meaningfully from mainstream endocrinology - particularly the emphasis on pure T3, physiological pulsed dosing, and anti-stress framing of thyroid hormone.
This article is a research-focused overview of the Dinkov / bioenergetic position on T3: the rationale, the dosing approaches most frequently discussed in that community, and how slow-release T3 (SRT3) formulations fit into the picture.
Research Grade · Discreet Worldwide Shipping
SRT3-15 Slow Release T3
Research framing. This article reviews a published-in-public framework around T3 research and the dosing patterns commonly discussed in the bioenergetic community. It is not medical advice. T3 reference standards on this site are sold strictly for laboratory research and are not approved for human consumption. See our research-use-only disclaimer.
The Bioenergetic Framing of T3
The mainstream view treats T3 as the active form of thyroid hormone, primarily relevant to people with diagnosed hypothyroidism, and replacement is generally accomplished with T4 (levothyroxine) on the assumption that the body will convert T4 to T3 as needed.
The bioenergetic view - which Dinkov has done as much as anyone to popularize - rejects several pieces of this:
- T3 is the actually-bioactive hormone. T4 is a prohormone. Reliance on T4-to-T3 conversion assumes that conversion is unimpaired - which it frequently is not under stress, inflammation, fasting, PUFA exposure, or estrogen dominance.
- Reverse T3 (rT3) acts as a brake. When the body is stressed (illness, starvation, chronic inflammation), T4 preferentially converts to reverse T3, which occupies T3 receptors without activating them. This is a stress adaptation that the bioenergetic model views as actively suppressive and worth correcting.
- T3 is a stress-protective and anti-inflammatory hormone. The Dinkov framework cites research showing T3 reduces serotonin signaling, increases dopamine, reduces cortisol burden, supports mitochondrial respiration over glycolysis, and exerts direct anti-inflammatory effects independent of metabolic rate.
- Pulsed delivery matters. Endogenous T3 release has a pulsatile circadian pattern. Once-daily fast-release T3 produces an unphysiological spike-and-trough profile. Slow-release T3 - or split dosing of fast-release T3 - more closely mimics the physiological pattern.
The T3 Dosing Approaches Most Discussed in This Framework
Across Dinkov's writing and adjacent bioenergetic-community discussion, several T3 research protocols recur. The numbers below reflect what is most commonly discussed in that community rather than any officially endorsed dosing.
1. Cyclic T3 (Wilson's Temperature Syndrome protocol)
Originally developed by Dr. Denis Wilson for what he calls Wilson's Temperature Syndrome, this is the protocol Dinkov most often cites for breaking out of reverse-T3 dominance. The principle is to overwhelm the rT3 brake with sustained T3 levels for long enough that the rT3 clears.
| Parameter | Typical research range |
|---|---|
| Form | Pure T3 (liothyronine), preferably sustained-release |
| Starting dose | 7.5 mcg slow-release T3, every 12 hours |
| Titration step | +7.5 mcg per 12 h every 1-3 days |
| Target | Sustained body temperature of 98.6°F (37.0°C) for 3 consecutive weeks |
| Tapering | Wean by 7.5 mcg per 12 h every 1-3 days once target temp is sustained |
The bioenergetic argument for this protocol is that the prolonged saturated T3 exposure resets the deiodinase enzyme balance, allowing endogenous T4-to-T3 conversion to resume normally after the cycle ends.
2. Continuous low-dose split T3
For research subjects not in active rT3 dominance, the Dinkov-style framing more often recommends a continuous low-dose split:
| Parameter | Typical research range |
|---|---|
| Form | Fast-release T3, or sustained-release at low dose |
| Daily total | 25-50 mcg/day for "physiological supplementation," up to 75-100 mcg/day in "active research" framing |
| Split | 3-5 doses per day (every 3-4 waking hours), or 2 doses of sustained-release |
| Timing | First dose on waking, last dose 4-6 h before sleep |
The rationale is that pulsed/split delivery never produces the unphysiological peak that one-shot 50 mcg fast-release dosing produces, while keeping serum T3 in a more constantly elevated range.
3. T4:T3 ratio dosing (NDT-style)
Dinkov frequently discusses the natural desiccated thyroid (NDT) ratio as a starting point - roughly 4:1 T4 to T3 by weight (matching pig thyroid composition, used in Armour-style preparations). For research purposes, this might be approximated as:
- 100 mcg T4 + 25 mcg T3 daily, split into 2 doses
The bioenergetic critique of NDT specifically is that the T4:T3 ratio in NDT is higher than what humans actually need (humans secrete more like 14:1, but absorb and convert variably). Many in the community shift to lower-T4 / higher-T3 ratios than NDT over time.
4. Pure T3 + supportive co-factors
Dinkov often references supportive nutrients alongside T3 dosing:
- Niacinamide (vitamin B3 amide form) - cited for its support of NAD+ and respiration
- Vitamin K2 (MK-4) - cited for steroidogenesis and bone protection during T3 dosing
- Aspirin at low dose - cited for anti-inflammatory effects synergistic with T3
- Pregnenolone - cited as upstream steroid precursor depleted by chronic stress
These are not part of any officially recognized protocol but appear repeatedly in his published reasoning.
Why Slow-Release T3 Specifically?
Fast-release T3 (e.g., Cytomel) reaches peak serum levels in ~2 hours and has a serum half-life of ~24 hours but a tissue/receptor half-life much shorter. The result is a sharp peak followed by a trough.
Slow-release T3 (SRT3) formulations - typically using HPMC (hydroxypropyl methylcellulose) as the slow-release matrix - extend the release window over 4-8 hours. The bioenergetic argument for SRT3 over fast-release T3:
- Reduced palpitations and anxiety at the spike of fast-release T3
- Smoother feedback suppression of TSH, allowing the HPT axis to find equilibrium
- Better tolerability of higher cumulative daily doses because no single dose produces a supraphysiological peak
- Cleaner overnight coverage when the second daily dose is taken in the early afternoon
Our SRT3 formulations use a two-excipient profile - HPMC + MCC only - with no dyes, gums, lactose, or surfactants commonly found in compounded T3. The 4-8 hour release window aligns with what the bioenergetic community most often calls for.
What the Published Literature Supports
Honest framing of what is well-established vs. what is community theory:
- Well-established: T3 acts on mitochondria to upregulate respiration. T3 reduces serotonin synthesis and increases dopamine signaling. T3 has direct anti-inflammatory effects. Reverse T3 occupies T3 receptors without activating them. Pulsatile T3 release is the physiological pattern.
- Reasonably-supported: chronic stress, inflammation, and PUFA load impair T4-to-T3 conversion. Some patients on T4-only therapy report symptom resolution only when T3 is added.
- Hypothesis / community theory: the rT3-dominance framework as a clinical entity (Wilson's Temperature Syndrome is not recognized by mainstream endocrinology). Specific bioenergetic dosing protocols. Co-factor combinations with niacinamide / K2 / pregnenolone.
The bioenergetic community's strength is taking real published mechanisms and connecting them into a coherent framework; its weakness is sometimes overstating the clinical generalizability of that framework. Both are worth understanding when evaluating T3 research protocols.
FAQ
Who is Georgi Dinkov and why is his T3 research notable?
Georgi Dinkov is a prolific writer in the bioenergetic / Ray-Peat-influenced corner of metabolic research, best known for his Haidut.me site and decade-plus archive of study commentary. His work has popularized the view of T3 as a central anti-stress, anti-inflammatory, pro-respiration hormone - not merely a thyroid-replacement molecule - and has influenced a generation of researchers exploring pulsed T3 dosing, T3-to-T4 ratios, and reverse-T3 dominance.
What is the Dinkov-style cyclic T3 protocol?
The cyclic T3 protocol most associated with the Dinkov framework is Dr. Denis Wilson's WT3 protocol: pure sustained-release T3 starting at 7.5 mcg every 12 hours, titrating up by 7.5 mcg every 1-3 days until body temperature sustains at 98.6°F for 3 consecutive weeks, then weaning back down at the same rate. The principle is to overwhelm reverse-T3 dominance with sustained T3 exposure.
Why does Dinkov favor T3 over T4?
The bioenergetic position is that T4 is a prohormone whose conversion to active T3 is impaired under stress, inflammation, fasting, estrogen dominance, and PUFA exposure - all common in modern life. Dosing T3 directly bypasses the conversion bottleneck. Reverse T3 (rT3) is also produced from T4 and acts as a competitive inhibitor at the T3 receptor; high T4 input under stress conditions can paradoxically suppress T3 signaling.
What is the typical T3 daily dose range in this framework?
For continuous low-dose research framing, 25-50 mcg/day total is most commonly cited. For active cyclic T3 protocols targeting rT3 dominance, daily totals can reach 75-150 mcg or more, always split into multiple doses through the day rather than taken as a single bolus.
Why is slow-release T3 (SRT3) preferred?
Fast-release T3 produces a sharp serum spike that the bioenergetic framing considers unphysiological - endogenous T3 release is pulsatile and steady. Slow-release T3 (using HPMC as the release-extending matrix) spreads delivery over 4-8 hours, producing a smoother serum curve, reducing palpitations and adrenergic side effects, and allowing higher cumulative daily doses to be tolerated. Our SRT3 line uses HPMC + MCC only - no fillers that might trigger MCAS or sensitivity in research subjects.
What co-factors does the bioenergetic T3 framework include?
Most commonly cited alongside T3 in this framework: niacinamide (NAD+ support), vitamin K2 (MK-4 form), low-dose aspirin (anti-inflammatory), pregnenolone (steroid precursor), and adequate sugar / orange juice in the diet to maintain glycogen reserves under increased metabolic rate. These are framework recommendations rather than officially endorsed protocols.
Closing Note
The bioenergetic case for T3 is not a contrarian rejection of endocrinology; it is a reframing that takes peer-reviewed mechanisms (T3 effects on mitochondria, serotonin, dopamine, reverse-T3 occupancy of the receptor) and assembles them into a coherent model where T3 is the protective, anti-stress, pro-respiration hormone rather than merely a thyroid-replacement molecule. Georgi Dinkov's writing has done as much as anyone to make this model accessible.
For researchers working in this space, sustained-release T3 with a minimal-excipient profile is the formulation most aligned with the bioenergetic dosing approach. See our SRT3 catalog for the full range of slow-release strengths.
Research compounds discussed in this article are sold strictly for laboratory study and are not approved for human consumption.